07th week of 2022 patent applcation highlights part 8 |
Patent application number | Title | Published |
20220047545 | Micronutrient combination to inhibit coronavirus cell infection - The way the SARS-CoV-2 virus infects the cell is a complex process and comprises four main stages: attachment to the cognate receptor, cellular entry, replication and cellular egress. Targeting binding of the virus to the host receptor in order to prevent its entry has been of particular interest. We tested 56 polyphenols, including plant extracts, brazilin, theaflavin-3,3′-digallate, and curcumin displayed the highest binding with the receptor-binding domain of spike protein, inhibiting viral attachment to the human angiotensin-converting enzyme 2 receptor, and thus cellular entry of pseudo-typed SARS-CoV-2 virions. Both, theaflavin-3,3′-digallate at 25 μg/ml and curcumin above 10 μg/ml concentration, showed binding with the angiotensin-converting enzyme 2 receptor reducing at the same time its activity in both cell-free and cell-based assays. Our study also demonstrates that brazilin and theaflavin-3, 3′-digallate, curcumin, decrease the activity of transmembrane serine protease 2 both in cell-free and cell-based assays and moderately increased endosomal/lysosomal pH. | 2022-02-17 |
20220047546 | COMBINATION CANCER THERAPIES - Drug combinations of a heteroarotinoid (e.g., SHetA2), and an Azabicyclooctan-3-one derivative (e.g., PRIMA-1 or PRIMA | 2022-02-17 |
20220047547 | SOLID ORAL PHARMACEUTICAL COMPOSITION - A solid oral pharmaceutical composition is disclosed, which comprises: a first active ingredient, which is pitavastatin or a pharmaceutically acceptable salt thereof; a second active ingredient, which is ezetimibe or a pharmaceutically acceptable salt thereof; and at least one excipient, including a diluent, a stabilizing agent, a disintegrant, a binding agent, a sweetener, a lubricant, a glidant, a flavor, a coloring agent or a combination thereof. | 2022-02-17 |
20220047548 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO - The present invention relates to a composition of the enantiomers of 2-(2-oxopyrrolidin-1-yl)butanamide and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from seizure-related disorders, peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment. | 2022-02-17 |
20220047549 | ENALAPRIL FORMULATIONS - Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction. | 2022-02-17 |
20220047550 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISORDERS - The present disclosure relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based compounds. More particularly, the present disclosure provides a class of compounds that can inhibit and/or attenuate apoptosis via caspase 3 for the treatment of various degenerative disorders. Additionally, the present disclosure relates to methods for treating specific degenerative disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, spinal cord injury, complication due to diabetes, multiple sclerosis (MS), muscular dystrophy (MD), Parkinson's disease (PD), irritable bowel syndrome (IBS) and Alzheimer's disease (AD) in a patient comprising administering to the patient an effective amount of a present compound. | 2022-02-17 |
20220047551 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF - The invention provides a method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof by administering an agent containing, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, to a patient that complies with specific criteria. The agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period. | 2022-02-17 |
20220047552 | RAF-1 KINASE INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF - The present invention relates to novel Raf-1 kinase inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery. | 2022-02-17 |
20220047553 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE - Described herein are combination therapies with famesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with famesoid X receptor activity. | 2022-02-17 |
20220047554 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS - The disclosure provides methods for treating a subject suffering from a disease associated with sodium channel activity. The method comprises administering to the subject a therapeutically effective amount of a compound according to Formula II or Formula III described in the specification, or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof. | 2022-02-17 |
20220047555 | ANTIMICROBIAL DRUG SYNTHESIS AND THERAPEUTIC COMPOSITIONS - This invention relates to the medical use of an antimicrobial agent, racemic Ornidazole, its (R) and (S) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with Ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives. The invention also relates to pharmaceutical formulations and compositions comprising (rac)-ornidazole, (R)-ornidazole, (S)-ornidazole, or pharmaceutically acceptable salts or esters thereof, and/or other actives as well as methods to stereoselectively manufacture the enantiomers. | 2022-02-17 |
20220047556 | USE OF SULCONAZOLE AS A FURIN INHIBITOR - The proprotein convertases (PCs) are implicated in the activation of various precursor proteins that play a crucial role in various cancers. Using structure-based virtual screening and a compound collection containing FDA approved drugs; the inventors identified Sulconazole as a small molecule able to repress furin activity. Moreover, the inventor show that Sulconazole is particularly suitable for repressing the expression of immune checkpoint protein (e.g. PD-1). 10 Therefore, Sulconazole would be particularly suitable for the treatment of disease involving furin activity in particular for the treatment of cancers. | 2022-02-17 |
20220047557 | TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL - Methods of inducing bradycardia (slowing a heart rate) in a subject in need thereof, treating a medical condition in which inducing bradycardia (slowing a heart rate) is desirable or beneficial in a subject in need thereof and/or treating a medical condition associated with cardiac arrhythmia, are provided. The methods are effected by blocking SK4 channel in SAN cell of the subject and/or by administering to the subject a therapeutically effective amount of a blocker of an SK4 channel. A method of identifying candidate compounds for treating an arrhythmic cardiac disorder, by identifying compounds that reduce a pacing rate of the SAN cells is also provided. | 2022-02-17 |
20220047558 | METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSIS - Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions. | 2022-02-17 |
20220047559 | DRUG COMPOSITION FOR TREATING BREAST CANCER AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a drug composition and method for treating breast cancer, and more specifically, to use carboxymethyl-hexanoyl chitosan (CHC) to co-encapsulate a heat shock protein 90 (HSP90) inhibitor and a hydrophobic drug. The two drugs can be co-encapsulated with high encapsulation efficiency and co-delivered to breast cancerous cells, and achieve a synergistic efficacy to kill the cancerous cells. | 2022-02-17 |
20220047560 | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF - A solid dosage form comprises an inner core containing a cycloserine compound and an outer layer attached to the inner core. The dosage form can be enteric tablet or transdermal patch, suitable for treating a neuropsychiatric disorder or tuberculosis. | 2022-02-17 |
20220047561 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF - Provided herein is salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I), wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided herein are methods for treating and/or reducing the risk of a neuropsychiatric disorder and/or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein. | 2022-02-17 |
20220047562 | TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA - The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score. | 2022-02-17 |
20220047563 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER - Methods for treating estrogen receptor positive (ER+) breast cancer, comprising administering to a subject in need thereof, a BET bromodomain inhibitor in combination with a second agent, selected from a selective-estrogen receptor degrader (SERD), a selective-estrogen receptor modulator (SERM) and a selective CDK4/6 inhibitor. The BET bromodomain inhibitor is selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo [4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof. | 2022-02-17 |
20220047564 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS - This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents. | 2022-02-17 |
20220047565 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST - Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided. | 2022-02-17 |
20220047566 | LONG ACTING IN-SITU FORMING/GELLING COMPOSITIONS - The present invention provides sustained release formulations comprising one or more active pharmaceutical ingredient(s); at least one biocompatible polymer excipient; and at least one biocompatible solvent; methods for preparing the sustained release formulations, and methods for treating localized pain in a subject in need thereof. | 2022-02-17 |
20220047567 | METHODS FOR THE TREATMENT OF NEUROFIBROMATOSIS - The invention relates to a PI3K inhibitor for use in the treatment of neurofibromatosis type 1 and type 2 in a subject in need thereof. Currently there are no treatment of neurofibromatosis type 1 and 2. Patients mainly received supportive care to treat severe symptoms including surgery to remove tumors compressing nearby tissue or damaging organs, stereotactic radiosurgery or cochlear implants. Inventors have worked on immortalized NF1−/− cells and shown that PIK3CA pharmacological inhibition (BYL719) was associated with increased apoptosis as assessed by PARP cleavage in a dose dependent manner. They also decided to expose NF1−/− cells to a multitargeted therapy including BYL719+selumetinib or BYL719+selumetinib+IPA-3. Importantly, they found that both combinations led to severe apoptosis with double strand DNA break as assessed by the phosphorylation of H2aX. This new approach with either BYL719 alone or in combination with other therapeutics seem to be very promising in patients with neurofibromatosis. | 2022-02-17 |
20220047568 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS - A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB | 2022-02-17 |
20220047569 | METHOD AND COMPOUND FOR USE, IN TREATING AND/OR PREVENTING NETOSIS - Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, prodrug, solvate, co-crystal, intermediate, pharmaceutically acceptable salt, metabolite, or composition thereof. The compound or its polymorph, stereoisomer, prodrug, solvate, co-crystal, intermediate, pharmaceutically acceptable salt, metabolite, or composition thereof may be used in for treating and/or preventing a disease or disorder or condition associated with NETosis. | 2022-02-17 |
20220047570 | MONTELUKAST FOR THE TREATMENT OF EROSIVE HAND OSTEOARTHRITIS - The present invention relates to montelukast for use in the treatment of erosive hand osteoarthritis. According to this use, montelukast can be administered either orally or topically, in the form of any suitable pharmaceutical composition. Patients suffering from erosive hand osteoarthritis treated with montelukast showed improvement in clinical symptoms and in radiological parameters, and also reported pain relief and hand functionality improvement. | 2022-02-17 |
20220047571 | COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-02-17 |
20220047572 | THERAPEUTIC AGENT FOR FIBROSIS - Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient. | 2022-02-17 |
20220047573 | METHODS FOR TREATING VASCULAR MALFORMATIONS - The present disclosure relates to methods for inhibiting TIE2 kinase useful in the treatment of growth of venous malformations. Specifically, the disclosure relates to methods of using a compound of Formula I and salts thereof | 2022-02-17 |
20220047574 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS - The present invention includes methods for treating a PDGFRα mutated proliferative disorder in a subject relapsed/refractory to prior tyrosine kinase inhibitor therapy comprising administering to the subject a therapeutically effective of crenolanib, | 2022-02-17 |
20220047575 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists. | 2022-02-17 |
20220047576 | QUINOLINE AMIDES AND METHODS OF USING SAME - The present invention provides novel compounds that are quinoline foldamers. Such foldamers stabilize and bind to islet amyloid polypeptide (IAPP). In certain embodiments, the quinoline foldamers of the invention are soluble and cross biological membranes without cellular assistance. The present invention further provides novel method of preventing or treating diabetes in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. The present invention further provides novel method of preventing or treating a neurodegenerative disease caused by a misfolded and/or unstructured protein in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. | 2022-02-17 |
20220047577 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS - The present invention includes methods for treating a PDGFRα mutated proliferative disorder in a subject relapsed/refractory to prior tyrosine kinase inhibitor therapy comprising administering to the subject a therapeutically effective of crenolanib, | 2022-02-17 |
20220047578 | ADMINISTRATION OF BERBERINE METABOLITES - In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds. | 2022-02-17 |
20220047579 | INJECTABLE SUSTAINED RELEASE BUPRENORPHINE FORMULATION - An injectable lipid-based suspension of buprenorphine providing one to seven days of pain alleviation has been developed. A method of manufacturing an injectable buprenorphine formulation providing about one to seven, preferably two to three, days of pain therapy, includes the steps of mixing buprenorphine and glyceryl tristearate dry powers, then mixing the resulting dry power blend with a liquid medium chain triglyceride (MCT), such as Miglyol 812, in a range of 0.2 to 20 mg Bup-GTS to one ml (or one gram) MCT. | 2022-02-17 |
20220047580 | METHOD FOR TREATING DRUG OR ALCOHOL DEPENDENCY - Provided herein is a method for weaning a subject suffering from a drug addiction or addictive behaviors involving opioid signaling by sequentially blocking peripheral and CNS opioid receptors and modulating opioid dependence. | 2022-02-17 |
20220047581 | METHODS OF TREATING RADIATION INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND RELATED DISEASE STATES USING COMPOUND 512 - The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof. | 2022-02-17 |
20220047582 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE - This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels. | 2022-02-17 |
20220047583 | PRODUCT AND METHOD FOR TREATING DIARRHEA - A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient. | 2022-02-17 |
20220047584 | METHOD OF TREATMENT FOR INFECTIVE ENDOCARDITIS - A method of treating or preventing endocarditis in a human patient in need of therapy is disclosed. The method comprises identifying a patient inflicted with or being at risk of contracting | 2022-02-17 |
20220047585 | PREVENTING OR TREATING AGENT FOR GLAUCOMA - A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided. | 2022-02-17 |
20220047586 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS - A composition and method for preventing or reducing the incidence of a transient ischemic attack in a subject at risk for developing a stroke comprises orally administering to the subject a prophylactically effective amount of a pharmaceutical composition comprising an ASIC1a inhibitor capable of penetrating the blood-brain barrier. Preferred ASIC1a inhibitors for use in the disclosed methods include amiloride and amiloride analogs. | 2022-02-17 |
20220047587 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO - The present invention relates to a composition of the enantiomers of 2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one derivatives and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment. | 2022-02-17 |
20220047588 | METHODS OF TREATING RHEUMATOID ARTHRITIS, CHRONIC SPONTANEOUS URTICARIA, AND SYSTEMIC LUPUS ERYTHEMATOSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE - The present disclosure relates to methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosus using fenebrutinib, an inhibitor of Bruton's tyrosine kinase, or a pharmaceutically acceptable salt thereof. | 2022-02-17 |
20220047589 | PDE9 INHIBITORS FOR TREATING THALASSEMIA - The present disclosure relates to PDE9 inhibitors, compositions comprising the PDE9 inhibitors, and methods of using the PDE9 inhibitors and compositions for treatment of thalassemia. | 2022-02-17 |
20220047590 | WOUND TREATMENTS AND COMPOSITIONS - A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and/or naltrexone. | 2022-02-17 |
20220047591 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NONALCOHOLIC FATTY LIVER DISEASE, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENT - The present invention pertains to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, the composition containing G protein coupled receptor 119 (GPR119) ligand as an active ingredient. The pharmaceutical composition according to the present invention exhibits the excellent effects of improving lipid metabolism, reducing fat accumulation in liver tissues, and preventing histological damage caused by inflammation and fibrosis in liver tissues, and can thus be useful in preventing or treating non-alcoholic fatty liver disease. | 2022-02-17 |
20220047592 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS - Provided herein are methods of treating a respiratory disease in a subject in need thereof by administering an effective amount of a small molecule C5a inhibitor. Also provided herein are methods of treating coronavirus disease 2019 (COVID-19) in a subject in need thereof by administering an effective amount of a small molecule C5a inhibitor. In some embodiments, the small molecule C5a inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV) or an embodiment described herein. | 2022-02-17 |
20220047593 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE - The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand. | 2022-02-17 |
20220047594 | METHOD FOR TREATING INTERSTITIAL LUNG DISEASE - There is a method of treating or preventing interstitial lung disease in a patient. The method includes the step of administering to the patient a therapeutically effective amount of the compound of the following formula: | 2022-02-17 |
20220047595 | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLI- N-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF - The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers. | 2022-02-17 |
20220047596 | COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCER - Provided herein are methods of treating cancer comprising administering a PARP inhibitor which may be combined with a BRD4 inhibitor. In one embodiment, the present disclosure provides a method for treating cancer in a subject comprising administering an effective amount of a poly-ADP-ribose polymerase (PARP) inhibitor in combination with a bromodomain-containing protein 4 (BRD4) inhibitor to the subject. In some aspects, the administration of the PARP inhibitor and BRD4 inhibitor results in greater reduction in tumor growth or greater reduction in tumor mass relative to administration of PARP inhibitor or BRD4 inhibitor alone. | 2022-02-17 |
20220047597 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER - The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods. | 2022-02-17 |
20220047598 | Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases - The present invention relates to the use of casein kinase 1 inhibitors for treating vascular diseases, preferably peripheral vascular diseases, and to corresponding treatment methods. | 2022-02-17 |
20220047599 | COMBINATION THERAPY OF SOLID CANCER - The present invention provides methods of treating solid cancer by co-administering an inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6) and multi-targeted receptor tyrosine kinase inhibitor (mt RTKI). Particular examples of CDK 4/6 inhibitor are palbociclib, abemaciclib and ribociclib and of mt RTKI are sunitinib, sorafenib and pazopanib. Administration of the combination may confer a synergic effect in treatment solid tumors. In particular synergic combinations of palbociclib with sunitinib or sorafenib are provided that synergically inhibit progression of a plurality of solid cancer types. The invention also provides pharmaceutical compositions comprising combinations of CDK 4/6 inhibitors and mt RTKIs and their use in treating solid cancer. | 2022-02-17 |
20220047600 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor. | 2022-02-17 |
20220047601 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS - The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation. | 2022-02-17 |
20220047602 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING - The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto. | 2022-02-17 |
20220047603 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES - The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which A, X, R | 2022-02-17 |
20220047604 | AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described. | 2022-02-17 |
20220047605 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 2022-02-17 |
20220047606 | TREATMENT METHOD WITH IAP INHIBITOR - Improved methods for treating hepatitis B (HB) in patients with (5S,5′S,8S,8′S,10aR,10a′R)-3,3′-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) (Compound (I)) are disclosed herein. Dosing regimens of Compound (I) for the treatment of HBV infection are provided. | 2022-02-17 |
20220047607 | METHODS OF TREATING NEURODEVELOPMENTAL DISORDERS - The invention relates to the treatment of neurodevelopmental disorders using an inhibitor of rho kinase. Preferred methods contemplate the treatment of infants and children. Certain embodiments involve treating a neurodevelopmental disorder is caused by defects of metabolism, including defects of amino acid transport or metabolism, acid-base balance, carbohydrate transport or metabolism, metal homeostasis, neurotransmitter metabolism, or fatty acid transport or metabolism. Methods address a variety of conditions caused by changes in the genetic material that affect the structure and/or expression of certain genes. Preferred methods treat Down syndrome, Fragile X syndrome, oligophrenin 1 deficiency, Rett syndrome, autistic disorder, Asperger's syndrome, pervasive developmental disorder not otherwise specified, and other autism spectrum disorders. | 2022-02-17 |
20220047608 | Method of Treatment and Pharmaceutical Composition for Morning Hypertension - The disclosure relates to methods and compositions for the treatment of one or more of morning hypertension and nocturnal hypertension. | 2022-02-17 |
20220047609 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS - The invention described herein relates to pharmaceutical compositions that are capable of delivering active pharmaceutical ingredients, such as estrogens, to the vagina and vagina-associated tissues and related methods of making and using such compositions (e.g., in the treatment of disease). Compositions of the invention are capable of being absorbed by the vagina or vagina-associated tissues such that subjects receiving treatment with the compositions may resume ambulatory activity immediately after receiving the treatment, the frequency or amount of discharge associated with the composition is low or negligible, there is little or no systemic absorption associated with the administration of the active pharmaceutical composition, or results in a combination of any or all thereof. | 2022-02-17 |
20220047610 | Inhalable Formulation of Fluticasone Propionate and Albuterol Sulfate - This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate. | 2022-02-17 |
20220047611 | Capsule, Tablet or Pill - Disclosed is a capsule, tablet or pill comprising a formulation at least two of the fat-soluble vitamins vitamin A, vitamin D, vitamin E and vitamin K; and one or more kinds of medium-chain triglyceride; also disclosed are foods, drinks and pharmaceutical compositions comprising the capsule, tablet or pill; and methods of treatment of a patient comprising administration of an effective amount of the capsule, tablet or pill. The capsule, tablet or pill is particularly, but not exclusively, suitable for use in treating cystic fibrosis patients. | 2022-02-17 |
20220047612 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME - Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease. | 2022-02-17 |
20220047613 | DUAL-DRUG CO-DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention discloses a dual-drug co-delivery system, a preparation method therefor and use thereof, the dual-drug co-delivery system being prepared from raw materials comprising a block copolymer, Homoharringtonine and Doxorubicin hydrochloride. The dual-drug co-delivery system provided by the present invention has a stronger killing effect on various hematologic tumors and solid tumor cells, can provide a feasible drug delivery system for inhibiting tumor growth and leukemia treatment, and has broad prospects. | 2022-02-17 |
20220047614 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS - The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation or ingestion of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses. | 2022-02-17 |
20220047615 | Immune Supplement Composition - The present invention provides compositions and methods for treating a subject infected with a human herpesvirus (HHV). In preferred embodiments, the subject compositions comprise tellimagrandin II, glycyrrhizin, monolaurin, selenium and one or more biological amphiphilic molecules, which, when administered to a subject can support immune health and suppress and/or disable viral pathogenic agents in the body. The invention can also be used for preventing reactivation of a latent HHV and treating and/or preventing diseases, disorders, conditions and/or comorbidities caused by and/or associated with HHV infection. | 2022-02-17 |
20220047616 | Method and Compositions for Treating HTLV-1 Virus Infection - A method of treating HTLV-1 virus infection. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises the combination of at least one cardiac glycoside and at least one, at least two, or at least three triterpenes. | 2022-02-17 |
20220047617 | Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof - Provided are a nucleic acid nanocarrier drug, a preparation method thereof, a pharmaceutical composition and an application thereof. The nucleic acid nanocarrier drug includes a nucleic acid nanoparticle carrier and a drug; and the nucleic acid nanoparticle includes a nucleic acid domain, the nucleic acid domain includes a sequence a, a sequence b and a sequence c, the sequence a includes a sequence a1 or a sequence obtained by insertion, deletion or substitution of at least one base in the sequence a1, the sequence b includes a sequence b1 or a sequence obtained by insertion, deletion or substitution of at least one base in the sequence b1, and the sequence c includes a sequence c1 or a sequence obtained by insertion, deletion or substitution of at least one base in the sequence c1. | 2022-02-17 |
20220047618 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS - Provided herein are methods for selectively delivering therapeutics to the eye using AAV vectors. For example, the cornea can be specifically targeted using the methods described. Also provided herein are compositions comprising AAV vectors packaged with CRISPR complexes, which can be delivered directly to the eye, for example the cornea, and in particular the cornea endothelium. Diseases and conditions comprising abnormalities or deterioration of tissues in the eye, such as the cornea endothelium (e.g. FECD), can be treated using the methods and compositions described herein. | 2022-02-17 |
20220047619 | RNA INTERFERENCE AGENTS FOR GST-PI GENE MODULATION - Compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications. | 2022-02-17 |
20220047620 | BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT - The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents. | 2022-02-17 |
20220047621 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION - The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described. | 2022-02-17 |
20220047622 | HYALURONAN COMPOSITIONS, AND USES THEREOF IN TREATMENT OF INTERSTITIAL CYSTITIS - A hydrogel composition for treatment of interstitial cystitis is described and comprises crosslinked hyaluronan particles dispersed throughout a crosslinked hyaluronan hydrogel matrix, wherein the hyaluronan is high molecular weight hyaluronan. The composition is formulated for direct bladder instillation in a human. The hyaluronan particles are nano-sized hyaluronan particles, or agglomerates of nano-sized hyaluronan particles, or a mixture thereof. | 2022-02-17 |
20220047623 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 2022-02-17 |
20220047624 | METHOD OF ADMINISTRATION AND TREATMENT - Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein. | 2022-02-17 |
20220047625 | HIGH-DOSE ANTIOXIDANTS IN CANCER TREATMENT - This invention proposes that a mixture of high doses of multiple antioxidants in combination with therapeutic agents may improve the management of cancer without toxicity. | 2022-02-17 |
20220047626 | COMPOSITION OF A SPRAY FORMULA TO CONTROL MASTITIS IN BOVINES - The present invention corresponds to the composition of a unique formula to be used as pre-dipping and post-dipping in robot milking in order to control mastitis in bovines. The composition comprises at least one organic zinc salt, water soluble and with biocidal properties, where the concentration of zinc ions is in the range of 5,000 to 60,000 ppm. The salts with biocidal properties were selected for having a functional group similar to proteins. Organic zinc salts are degradable, less irritating to the cow's teat, improve the skin condition, have an anti-inflammatory effect, accelerate wound healing processes and eliminate bacteria and fungi. The organic zinc salts selected for this invention were the following: gluconate, lactate, glycinate, lysinate, citrate trihydrate, picolinate, and acetate. Zinc sulfate monohydrate can be optionally added, but in low concentration, less than 1.5% of the final product. The viscosity of the spray composition should be in the range of 3 to 5 centipoise (cP), at room temperature. Finally, and very importantly, the composition has no corrosive activity on metals and non-metals, such as stainless steel, carbon steel, computer cards and other components found in bovine milking robots. | 2022-02-17 |
20220047627 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS - A method of managing non-infective nasal symptoms may include formulating a topical composition for nasal administration. The formulation may include zinc, acetylcysteine, azelastine, one or more probiotics, or a combination thereof. The formulation may also include additional ingredients such as a steroid, poloxamers, or xylitol. Ingredients of the topical composition may be provided in a dry powder format within a capsule for combining with an aqueous diluent at the time of administration. The topical composition may be administered nasally. | 2022-02-17 |
20220047628 | Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates - Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided. | 2022-02-17 |
20220047630 | BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES - The present invention relates to a method of preparing a barn dust extract, said barn dust extract, and a composition comprising said barn dust extract. The barn dust extract is useful in the prevention or treatment of a disease. | 2022-02-17 |
20220047631 | CANCER TREATMENT WITH 237 CAR-T CELL BASED THERAPEUTICS RECOGNIZING THE TN EPITOPE - The disclosure provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs, as well as methods of identifying cancer subjects and cancer subject sub-populations amenable to anti-Tn immunotherapy and methods of treating cancer. | 2022-02-17 |
20220047632 | PHARMACEUTICAL COMBINATIONS FOR TREATING TUMOR COMPRISING ANTI-CD19 ANTIBODY AND NATURAL KILLER CELL - Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia. | 2022-02-17 |
20220047633 | CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES - The invention provides compositions and methods for treating cancer, e.g., hematological cancer, by administering a CD22 CAR-expressing cell described herein according to a dosage regimen described herein. Also disclosed are methods of making and compositions comprising the same. | 2022-02-17 |
20220047634 | CHIMERIC ANTIGEN RECEPTOR FACTORIES AND METHODS OF USE THEREOF - This invention is directed to chimeric antigen receptors and cells comprising the same, wherein the cells further secrete monoclonal antibodies locally at a tumor site. | 2022-02-17 |
20220047635 | METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY - Several embodiments disclosed herein relate to methods and processes for the co-expansion of multiple types of immune cells, in order to generate a mixed cell population. Some embodiments relate to the use of various stimuli specific to the various subpopulations to achieve expansion of those subpopulations at a particular time in a culturing process in order to generate an expanded population of immune cells having a desired ratio of the various subpopulations. In several embodiments, such mixed cell populations exhibit desirable characteristics, such as cytotoxic effects against tumor cells that enhance the efficacy of cancer immunotherapy. | 2022-02-17 |
20220047636 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD79B AND CD19 - Described herein are upfront methods for treating a patient suffering from a cancer. The method includes administering to the patient a therapeutically effective amount of an anti-cancer therapy including a chimeric antigen receptor (CAR) including an extracellular domain including a CD79b-binding domain and a CD19-binding domain, wherein the patient has not been previously treated for the cancer. The invention accordingly also relates to methods of producing and utilizing, e.g., T cells including CARs having an extracellular domain that binds CD79b and CD19. | 2022-02-17 |
20220047637 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES - Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin. | 2022-02-17 |
20220047638 | USE OF STEM CELL EXOSOMES FOR TREATING OVERACTIVE BLADDER - The disclosure relates to use of stem cell exosomes in preparing a medicament for treating overactive bladder. It has been confirmed that stem cell exosomes are effective in the treatment of overactive bladder and can be used in preparing a medicament for treating overactive bladder. | 2022-02-17 |
20220047639 | Method of Preparing Hematopoietic Stem and Progenitor Cells for Transplantation - Disclosed are methods of preparing hematopoietic stem cells and progenitor cells (HSPCs) for transplant into a subject and to methods of using the treated cells. More particularly, methods of the invention comprise treating HSPCs ex vivo with an effective amount of a GABBR1 agonist and administering the treated HSPCs to the subject. | 2022-02-17 |
20220047640 | PHARMACEUTICAL COMPOSITION FOR TREATING PANCREATITIS, COMPRISING CLONAL STEM CELLS - The present disclosure relates to a composition for preventing, treating, or alleviating pancreatitis, containing monoclonal stem cells obtained by improved subfractionation culturing of stem cells, and to a method for preparing the same. According to the improved method of subfractionation culture and proliferation of stem cells of the present disclosure, it is possible to obtain a large quantity of desired monoclonal stem cells in a short time by rapid proliferation of monoclonal stem cells, and the monoclonal mesenchymal stem cells obtained thereby are stem cells with enhanced therapeutic effects on pancreatitis, and thus can may beneficially used as a pancreatitis therapeutic agent. | 2022-02-17 |
20220047641 | ACTIVATED STEM CELLS AND SYSTEMIC TREATMENT METHODS FOR INFECTED WOUNDS - Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal. | 2022-02-17 |
20220047642 | AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD - It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue. | 2022-02-17 |
20220047643 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY - Embodiments of the disclosure include methods and compositions related to treatment and prevention of an excess of cytokines in an individual using fibroblasts or fibroblast-derived microvesicles. In particular embodiments, there are methods and compositions for treating and preventing toxicities in an individual that may be the result of cytokine release syndrome. In specific cases, an individual is treated for cytokine release syndrome with fibroblasts having one or more specific markers. | 2022-02-17 |
20220047644 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - The present invention concerns methods and compositions for differentiating cells, including human fibroblasts, into chondrocyte-like cells via in vivo mechanical strain. In particular aspects, fibroblasts are delivered to a joint, such as an intervertebral disc, following which the fibroblasts differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. The fibroblasts that do not differentiate to chondrocytic cells because of the location of the cells, as in the fissures of annulus, or other biomechanical and biochemical micro-environment factors, may produce fibrous matrix molecule(s) in aiding tissue repair and regeneration in both nucleus pulposus and annulus fibrosus. In certain aspects, the fibroblasts prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 2022-02-17 |
20220047645 | METHOD FOR TREATING CARDIAC CONDITIONS WITH PLACENTA-DERVIVED COMPOSITIONS - Provided herein are compositions and methods for treating heart disease. In particular, provided herein are constructs, devices, and systems, each comprising one or more placenta-derived compositions, and their use in treating disorders involving aberrant cardiac rhythms and promoting repair of damaged cardiac tissue. The method of treatment comprises applying one or more constructs on the surface of all or a portion of the heart and/or adjacent tissues, during or after surgical heart treatment. | 2022-02-17 |